• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Psychemedics Releases 2026 Education Insights Report

    6/30/26 9:00:00 AM ET
    $PMD
    Medical Specialities
    Health Care
    Get the next $PMD alert in real time by email

    DALLAS, June 30, 2026 (GLOBE NEWSWIRE) -- Psychemedics Corporation, the pioneer and global leader in hair testing for drugs of abuse, today announced the release of its 2026 Education Insights Report, a comprehensive analysis of substance use trends affecting high school and college students across the United States.

    Combining national research with longitudinal hair testing data, the report explores the evolving landscape of student substance use, including cannabis, prescription stimulants, vaping products, synthetic opioids, and other emerging substances. The findings provide educational leaders with valuable insight into behavioral trends that may influence student well-being, academic performance, and campus safety.

    Key findings from the 2026 Education Insights Report include:

    • Student positivity rates reached a five-year low in 2025. The overall positive rate declined to 3.1%, down from a peak of 5.4% in 2022, suggesting that sustained prevention and education efforts can produce measurable results.
    • Marijuana remains the most commonly detected substance. Cannabis accounts for more than half of all positive results, reflecting the continued influence of high-potency products, vaping devices, edibles, and other alternative delivery methods.
    • Prescription drug threats continue to emerge. The increasing presence of counterfeit pills containing fentanyl and other synthetic opioids presents growing health and safety concerns for educational institutions.
    • Substance use remains closely tied to academic outcomes. Research reviewed in the report links substance use to reduced classroom engagement, increased absenteeism, lower academic performance, and decreased educational persistence.

    "Educational institutions today face challenges that extend far beyond the classroom," said Brian Hullinger, President and CEO of Psychemedics. "Student wellness, mental health, academic success, and campus safety are increasingly interconnected. The Education Insights Report is designed to help educators better understand evolving substance use trends and make informed decisions that support student achievement and well-being."

    The report also examines how emerging products such as Delta-8 THC, cannabis concentrates, vaping devices, and counterfeit prescription pills are reshaping risk patterns among adolescents and young adults. In addition, it highlights the value of longitudinal data in supporting prevention programs, wellness initiatives, and early intervention strategies.

    According to the report, while overall positivity rates have declined in recent years, cannabis continues to drive the majority of positive results, and substances such as cocaine, opioids, and prescription stimulants remain present within student populations. The findings underscore the importance of maintaining proactive approaches to student health and safety rather than relying solely on reactive policies.

    "Prevention starts with understanding," added Hullinger. "Schools and universities need reliable information about the challenges students are facing today. Our goal is to provide insights that help institutions create safer, healthier, and more supportive learning environments."

    The full 2026 Education Insights Report is available at: https://www.psychemedics.com/whitepaper/

    For more information about Psychemedics Corporation and its hair testing solutions, visit https://www.psychemedics.com.

    About Psychemedics 

    Psychemedics Corporation is the pioneer and a leading global provider of hair testing for drugs of abuse. With a commitment to accuracy and reliability, the company offers cutting-edge drug testing solutions. Psychemedics Corporation is dedicated to providing valuable insights and maintaining the highest standards in substance abuse testing.

    Investor Relations:

    Phone: 978-206-8220

    Email: InvestorRelations@psychemedics.com



    Primary Logo

    Get the next $PMD alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $PMD

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $PMD
    SEC Filings

    View All

    SEC Form 15-12G filed by Psychemedics Corporation

    15-12G - PSYCHEMEDICS CORP (0000806517) (Filer)

    1/2/25 4:10:54 PM ET
    $PMD
    Medical Specialities
    Health Care

    SEC Form 25 filed by Psychemedics Corporation

    25 - PSYCHEMEDICS CORP (0000806517) (Filer)

    12/13/24 8:00:57 AM ET
    $PMD
    Medical Specialities
    Health Care

    Amendment: SEC Form SC 13E3/A filed by Psychemedics Corporation

    SC 13E3/A - PSYCHEMEDICS CORP (0000806517) (Subject)

    12/10/24 4:46:00 PM ET
    $PMD
    Medical Specialities
    Health Care

    $PMD
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Psychemedics Releases 2026 Education Insights Report

    DALLAS, June 30, 2026 (GLOBE NEWSWIRE) -- Psychemedics Corporation, the pioneer and global leader in hair testing for drugs of abuse, today announced the release of its 2026 Education Insights Report, a comprehensive analysis of substance use trends affecting high school and college students across the United States. Combining national research with longitudinal hair testing data, the report explores the evolving landscape of student substance use, including cannabis, prescription stimulants, vaping products, synthetic opioids, and other emerging substances. The findings provide educational leaders with valuable insight into behavioral trends that may influence student well-being, academi

    6/30/26 9:00:00 AM ET
    $PMD
    Medical Specialities
    Health Care

    Psychemedics Releases 2026 Workforce Insights Report

    New Data Highlights Shifting Drug Trends, Industry Risk Patterns, and the Growing Importance of Long-Window Testing DALLAS, April 30, 2026 (GLOBE NEWSWIRE) -- Psychemedics Corporation, a global leader in hair testing for drugs of abuse, today announced the release of its 2026 Workforce Insights Report, offering an in-depth analysis of drug use trends across the modern workforce and their implications for workplace safety, hiring practices, and employer risk management. The annual report draws on Psychemedics' extensive proprietary database of hair drug testing results, analyzing hundreds of thousands of samples collected during 2025 across multiple industries, including transportation,

    4/30/26 10:00:00 AM ET
    $PMD
    Medical Specialities
    Health Care

    Psychemedics Releases 2025 Workforce Insights Report

    DALLAS, June 16, 2025 (GLOBE NEWSWIRE) -- Psychemedics Corporation, a global leader in hair testing for drugs of abuse, today announced the release of its second annual Workforce Insights Report, providing a comprehensive look at the evolving drug landscape and its impact on workplace safety, hiring practices, and employer risk. The 2025 Psychemedics Insights Report draws from the largest proprietary database of hair drug testing results in the industry, analyzing hundreds of thousands of samples collected in 2024 across a wide range of sectors, including transportation, manufacturing, healthcare, government, and more. The report reveals critical workforce trends and emerging threats empl

    6/16/25 9:00:00 AM ET
    $PMD
    Medical Specialities
    Health Care

    $PMD
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Powell Anderson Capital Partners Llc bought $305,439 worth of shares (159,700 units at $1.91) (SEC Form 4)

    4 - PSYCHEMEDICS CORP (0000806517) (Issuer)

    12/17/24 8:29:49 PM ET
    $PMD
    Medical Specialities
    Health Care

    Large owner Powell Anderson Capital Partners Llc bought $231,849 worth of shares (86,991 units at $2.67) (SEC Form 4)

    4 - PSYCHEMEDICS CORP (0000806517) (Issuer)

    12/12/24 8:41:51 PM ET
    $PMD
    Medical Specialities
    Health Care

    Director Kamin Peter bought $3,312,823 worth of shares (1,409,712 units at $2.35) (SEC Form 4)

    4 - PSYCHEMEDICS CORP (0000806517) (Issuer)

    12/5/24 6:05:08 PM ET
    $PMD
    Medical Specialities
    Health Care

    $PMD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Powell Anderson Capital Partners Llc bought $305,439 worth of shares (159,700 units at $1.91) (SEC Form 4)

    4 - PSYCHEMEDICS CORP (0000806517) (Issuer)

    12/17/24 8:29:49 PM ET
    $PMD
    Medical Specialities
    Health Care

    Large owner Powell Anderson Capital Partners Llc bought $231,849 worth of shares (86,991 units at $2.67) (SEC Form 4)

    4 - PSYCHEMEDICS CORP (0000806517) (Issuer)

    12/12/24 8:41:51 PM ET
    $PMD
    Medical Specialities
    Health Care

    Director Kamin Peter sold $753,664 worth of shares (320,708 units at $2.35) (SEC Form 4)

    4 - PSYCHEMEDICS CORP (0000806517) (Issuer)

    12/12/24 5:15:34 PM ET
    $PMD
    Medical Specialities
    Health Care

    $PMD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Psychemedics Corporation

    SC 13D/A - PSYCHEMEDICS CORP (0000806517) (Subject)

    12/12/24 5:15:40 PM ET
    $PMD
    Medical Specialities
    Health Care

    Amendment: SEC Form SC 13G/A filed by Psychemedics Corporation

    SC 13G/A - PSYCHEMEDICS CORP (0000806517) (Subject)

    12/6/24 9:18:20 PM ET
    $PMD
    Medical Specialities
    Health Care

    Amendment: SEC Form SC 13D/A filed by Psychemedics Corporation

    SC 13D/A - PSYCHEMEDICS CORP (0000806517) (Subject)

    12/5/24 6:04:48 PM ET
    $PMD
    Medical Specialities
    Health Care

    $PMD
    Leadership Updates

    Live Leadership Updates

    View All

    Psychemedics Corporation Appoints Daniella Mehalik as VP - Finance

    ACTON, Mass., Nov. 27, 2023 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ:PMD), a global leader in hair testing for substance abuse, proudly announces the appointment of Daniella Mehalik as its new Vice President - Finance. In her new role, Ms. Mehalik will assume responsibility for directing and managing all financial activities at Psychemedics, including comprehensive oversight of external reporting and internal analysis. Reporting directly to CEO and President Brian Hullinger, she will play a pivotal role in steering the financial trajectory of the organization. Bringing over a decade of extensive experience to her new position, Ms. Mehalik possesses a robust background in acco

    11/27/23 9:00:00 AM ET
    $NBSE
    $PMD
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical Specialities

    Psychemedics Corporation Reports Third Quarter 2023 Financial Results

    ACTON, Mass., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ:PMD), a leading provider of hair testing for drugs of abuse, today announced financial results for the third quarter ended September 30, 2023. The Company's revenue for the quarter ended September 30, 2023, was $5.7 million versus $6.5 million for the quarter ended September 30, 2022, a decrease of 12%. Net loss for the quarter ended September 30, 2023, was $(2.1 million) or $(0.36) per diluted share, versus net loss of $(97,000) or $(0.02) per diluted share, for the comparable period last year. The Company has initiated a series of restructuring changes that will align costs with current revenue trends. Res

    11/9/23 5:00:59 PM ET
    $PMD
    Medical Specialities
    Health Care

    Psychemedics Corporation Appoints Shannon Shoemaker as Chief Revenue Officer

    ACTON, Mass., Sept. 21, 2023 (GLOBE NEWSWIRE) -- Psychemedics Corporation, the world's largest provider of hair testing for drugs of abuse, is pleased to announce the appointment of Shannon Shoemaker as its new Chief Revenue Officer. In this role, Shoemaker will be responsible for overseeing the company's revenue generation and growth strategies. With an exceptional track record of leadership and a strong background in revenue growth and optimization, Shoemaker brings a wealth of experience to her new position. Her appointment marks a significant milestone for Psychemedics Corporation as it continues to expand its presence in the rapidly evolving field of substance abuse testing. "We are

    9/21/23 5:00:00 PM ET
    $PMD
    Medical Specialities
    Health Care

    $PMD
    Financials

    Live finance-specific insights

    View All

    Unveiling the Future of Drug Testing: Psychemedics Introduces Advanced 5-Panel Drug Screen

    ACTON, Mass., Oct. 27, 2023 (GLOBE NEWSWIRE) -- In an era marked by relentless change and the pressing need to adapt, Psychemedics, a pioneer in the drug screening industry, proudly announces the launch of a revolutionary, Advanced 5-Panel Drug Screen. This groundbreaking offering will transform the way organizations safeguard their workplaces, shifting the spotlight from marijuana to the paramount threat of fentanyl. Complemented by the detection of cocaine, opioids, PCP, and amphetamines, the advanced panel is a leap forward in drug screening technology. As we grapple with an ongoing labor shortage and with marijuana's legal landscape evolving in 49 states, it's clear that the time for

    10/27/23 11:00:00 AM ET
    $PMD
    Medical Specialities
    Health Care

    Psychemedics Corporation Reports Second Quarter 2023 Financial Results

    ACTON, Mass., Aug. 11, 2023 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ:PMD), the world's largest provider of hair testing for drugs of abuse, today announced financial results for the second quarter ended June 30, 2023. The Company's revenue for the quarter ended June 30, 2023, was $5.5 million versus $6.5 million for the quarter ended June 30, 2022, a decrease of 15%. Net loss for the quarter ended June 30, 2023, was $(726,000) or $(0.13) per diluted share, versus net loss of $(338,000) or $(0.06) per diluted share, for the comparable period last year. In the second quarter, the labor shortage continued to have an adverse impact on our clients' use of hair testing in hirin

    8/11/23 5:10:31 PM ET
    $PMD
    Medical Specialities
    Health Care

    Psychemedics Corporation Reports First Quarter 2023 Financial Results and Declares Cash Dividend

    ACTON, Mass., May 09, 2023 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ:PMD), the world's largest provider of hair testing for drugs of abuse, today announced financial results for the first quarter ended March 31, 2023, and the declaration of a cash dividend of $0.07 per share to be paid on June 8, 2023, to shareholders of record as of May 25, 2023. The Company's revenue for the quarter ended March 31, 2023, was $5.9 million versus $6.5 million for the quarter ended March 31, 2022, a decrease of 10%. Net loss for the quarter ended March 31, 2023, was $(384,000) or $(0.07) per diluted share, versus net income of $39,000 or $0.01 per diluted share, for the comparable period last ye

    5/9/23 5:30:00 PM ET
    $PMD
    Medical Specialities
    Health Care